nodes	percent_of_prediction	percent_of_DWPC	metapath
Bismuth Subsalicylate—PTGS2—skin cancer	0.498	1	CbGaD
Bismuth Subsalicylate—ALB—Vismodegib—skin cancer	0.151	0.466	CbGbCtD
Bismuth Subsalicylate—ALB—Vemurafenib—skin cancer	0.12	0.368	CbGbCtD
Bismuth Subsalicylate—ALB—Fluorouracil—skin cancer	0.0538	0.166	CbGbCtD
Bismuth Subsalicylate—Warts—Imiquimod—skin cancer	0.0151	0.116	CcSEcCtD
Bismuth Subsalicylate—Skin papilloma—Vemurafenib—skin cancer	0.00627	0.0481	CcSEcCtD
Bismuth Subsalicylate—Skin papilloma—Imiquimod—skin cancer	0.00535	0.041	CcSEcCtD
Bismuth Subsalicylate—TF—blood vessel—skin cancer	0.0051	0.111	CbGeAlD
Bismuth Subsalicylate—Localized exfoliation—Bleomycin—skin cancer	0.0046	0.0352	CcSEcCtD
Bismuth Subsalicylate—PTGS2—leg—skin cancer	0.00339	0.0736	CbGeAlD
Bismuth Subsalicylate—PTGS2—hindlimb—skin cancer	0.00303	0.0658	CbGeAlD
Bismuth Subsalicylate—TF—connective tissue—skin cancer	0.00262	0.0568	CbGeAlD
Bismuth Subsalicylate—PTGS2—appendage—skin cancer	0.0026	0.0564	CbGeAlD
Bismuth Subsalicylate—TF—epithelium—skin cancer	0.00248	0.0539	CbGeAlD
Bismuth Subsalicylate—Hyponatraemia—Vismodegib—skin cancer	0.00241	0.0185	CcSEcCtD
Bismuth Subsalicylate—TF—skin of body—skin cancer	0.00236	0.0513	CbGeAlD
Bismuth Subsalicylate—Abdominal pain upper—Vismodegib—skin cancer	0.00219	0.0168	CcSEcCtD
Bismuth Subsalicylate—PTGS2—skin epidermis—skin cancer	0.00216	0.0469	CbGeAlD
Bismuth Subsalicylate—Stinging—Imiquimod—skin cancer	0.00215	0.0165	CcSEcCtD
Bismuth Subsalicylate—TF—lymphoid tissue—skin cancer	0.00191	0.0415	CbGeAlD
Bismuth Subsalicylate—TF—female reproductive system—skin cancer	0.00185	0.0401	CbGeAlD
Bismuth Subsalicylate—Skin exfoliation—Imiquimod—skin cancer	0.00166	0.0128	CcSEcCtD
Bismuth Subsalicylate—PTGS1—endothelium—skin cancer	0.00164	0.0356	CbGeAlD
Bismuth Subsalicylate—PTGS2—endothelium—skin cancer	0.00157	0.0341	CbGeAlD
Bismuth Subsalicylate—TF—head—skin cancer	0.00154	0.0335	CbGeAlD
Bismuth Subsalicylate—PTGS1—blood vessel—skin cancer	0.00151	0.0329	CbGeAlD
Bismuth Subsalicylate—Lung disorder—Temozolomide—skin cancer	0.00148	0.0113	CcSEcCtD
Bismuth Subsalicylate—PTGS2—blood vessel—skin cancer	0.00145	0.0314	CbGeAlD
Bismuth Subsalicylate—Duodenal ulcer—Docetaxel—skin cancer	0.00144	0.011	CcSEcCtD
Bismuth Subsalicylate—Extravasation—Bleomycin—skin cancer	0.00142	0.0109	CcSEcCtD
Bismuth Subsalicylate—Dysgeusia—Vismodegib—skin cancer	0.00142	0.0109	CcSEcCtD
Bismuth Subsalicylate—Heartburn—Fluorouracil—skin cancer	0.0014	0.0107	CcSEcCtD
Bismuth Subsalicylate—Extravasation—Dactinomycin—skin cancer	0.00132	0.0101	CcSEcCtD
Bismuth Subsalicylate—Lethargy—Imiquimod—skin cancer	0.00129	0.00989	CcSEcCtD
Bismuth Subsalicylate—Stinging—Fluorouracil—skin cancer	0.00119	0.0091	CcSEcCtD
Bismuth Subsalicylate—Skin exfoliation—Bleomycin—skin cancer	0.00118	0.00906	CcSEcCtD
Bismuth Subsalicylate—Extravasation—Fluorouracil—skin cancer	0.0011	0.00845	CcSEcCtD
Bismuth Subsalicylate—Hearing impaired—Temozolomide—skin cancer	0.0011	0.00841	CcSEcCtD
Bismuth Subsalicylate—PTGS1—nipple—skin cancer	0.00109	0.0238	CbGeAlD
Bismuth Subsalicylate—TF—lymph node—skin cancer	0.00108	0.0234	CbGeAlD
Bismuth Subsalicylate—Oesophagitis—Dactinomycin—skin cancer	0.00105	0.00809	CcSEcCtD
Bismuth Subsalicylate—Phlebitis—Bleomycin—skin cancer	0.00104	0.008	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Vismodegib—skin cancer	0.00104	0.00796	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Vismodegib—skin cancer	0.00103	0.00786	CcSEcCtD
Bismuth Subsalicylate—Heartburn—Docetaxel—skin cancer	0.00101	0.00773	CcSEcCtD
Bismuth Subsalicylate—Pain—Vismodegib—skin cancer	0.00101	0.00773	CcSEcCtD
Bismuth Subsalicylate—Constipation—Vismodegib—skin cancer	0.00101	0.00773	CcSEcCtD
Bismuth Subsalicylate—Burning sensation—Docetaxel—skin cancer	0.001	0.00766	CcSEcCtD
Bismuth Subsalicylate—Skin exfoliation—Temozolomide—skin cancer	0.000997	0.00764	CcSEcCtD
Bismuth Subsalicylate—Phlebitis—Dactinomycin—skin cancer	0.000973	0.00746	CcSEcCtD
Bismuth Subsalicylate—Erythema multiforme—Vemurafenib—skin cancer	0.00097	0.00744	CcSEcCtD
Bismuth Subsalicylate—Erythema—Vemurafenib—skin cancer	0.000893	0.00685	CcSEcCtD
Bismuth Subsalicylate—Oesophagitis—Fluorouracil—skin cancer	0.000879	0.00674	CcSEcCtD
Bismuth Subsalicylate—Dysgeusia—Vemurafenib—skin cancer	0.000875	0.0067	CcSEcCtD
Bismuth Subsalicylate—Lethargy—Dactinomycin—skin cancer	0.000855	0.00656	CcSEcCtD
Bismuth Subsalicylate—Deafness—Temozolomide—skin cancer	0.000847	0.0065	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Vismodegib—skin cancer	0.000835	0.0064	CcSEcCtD
Bismuth Subsalicylate—Erythema multiforme—Imiquimod—skin cancer	0.000827	0.00634	CcSEcCtD
Bismuth Subsalicylate—Tinnitus—Imiquimod—skin cancer	0.000816	0.00625	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Vismodegib—skin cancer	0.000807	0.00619	CcSEcCtD
Bismuth Subsalicylate—Extravasation—Docetaxel—skin cancer	0.000796	0.0061	CcSEcCtD
Bismuth Subsalicylate—PTGS1—connective tissue—skin cancer	0.000776	0.0168	CbGeAlD
Bismuth Subsalicylate—Erythema—Imiquimod—skin cancer	0.000762	0.00584	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Vismodegib—skin cancer	0.00075	0.00575	CcSEcCtD
Bismuth Subsalicylate—Rash—Vismodegib—skin cancer	0.000744	0.0057	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Vismodegib—skin cancer	0.000743	0.0057	CcSEcCtD
Bismuth Subsalicylate—PTGS2—connective tissue—skin cancer	0.000742	0.0161	CbGeAlD
Bismuth Subsalicylate—PTGS1—epithelium—skin cancer	0.000737	0.016	CbGeAlD
Bismuth Subsalicylate—Hearing impaired—Docetaxel—skin cancer	0.00073	0.00559	CcSEcCtD
Bismuth Subsalicylate—Infection—Vemurafenib—skin cancer	0.000724	0.00555	CcSEcCtD
Bismuth Subsalicylate—Lethargy—Fluorouracil—skin cancer	0.000713	0.00546	CcSEcCtD
Bismuth Subsalicylate—PTGS2—epithelium—skin cancer	0.000704	0.0153	CbGeAlD
Bismuth Subsalicylate—Nausea—Vismodegib—skin cancer	0.000701	0.00537	CcSEcCtD
Bismuth Subsalicylate—PTGS1—skin of body—skin cancer	0.000701	0.0152	CbGeAlD
Bismuth Subsalicylate—PTGS2—skin of body—skin cancer	0.00067	0.0145	CbGeAlD
Bismuth Subsalicylate—Skin exfoliation—Docetaxel—skin cancer	0.000663	0.00508	CcSEcCtD
Bismuth Subsalicylate—PTGS1—mammalian vulva—skin cancer	0.000639	0.0139	CbGeAlD
Bismuth Subsalicylate—Oesophagitis—Docetaxel—skin cancer	0.000635	0.00486	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Vemurafenib—skin cancer	0.000634	0.00486	CcSEcCtD
Bismuth Subsalicylate—Constipation—Vemurafenib—skin cancer	0.000623	0.00478	CcSEcCtD
Bismuth Subsalicylate—Oedema—Imiquimod—skin cancer	0.000622	0.00477	CcSEcCtD
Bismuth Subsalicylate—Lightheadedness—Docetaxel—skin cancer	0.000621	0.00476	CcSEcCtD
Bismuth Subsalicylate—Infection—Imiquimod—skin cancer	0.000618	0.00473	CcSEcCtD
Bismuth Subsalicylate—Weight increased—Temozolomide—skin cancer	0.000596	0.00457	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Imiquimod—skin cancer	0.000593	0.00454	CcSEcCtD
Bismuth Subsalicylate—Phlebitis—Docetaxel—skin cancer	0.000585	0.00449	CcSEcCtD
Bismuth Subsalicylate—Hepatitis—Dactinomycin—skin cancer	0.00058	0.00444	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Vemurafenib—skin cancer	0.000576	0.00442	CcSEcCtD
Bismuth Subsalicylate—Deafness—Docetaxel—skin cancer	0.000563	0.00432	CcSEcCtD
Bismuth Subsalicylate—ALB—lymph node—skin cancer	0.000562	0.0122	CbGeAlD
Bismuth Subsalicylate—Somnolence—Imiquimod—skin cancer	0.000553	0.00424	CcSEcCtD
Bismuth Subsalicylate—Erythema multiforme—Dactinomycin—skin cancer	0.000548	0.0042	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Imiquimod—skin cancer	0.000547	0.00419	CcSEcCtD
Bismuth Subsalicylate—PTGS1—female reproductive system—skin cancer	0.000547	0.0119	CbGeAlD
Bismuth Subsalicylate—PTGS2—lymphoid tissue—skin cancer	0.000542	0.0118	CbGeAlD
Bismuth Subsalicylate—Erythema—Bleomycin—skin cancer	0.000541	0.00415	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Imiquimod—skin cancer	0.00054	0.00414	CcSEcCtD
Bismuth Subsalicylate—Pain—Imiquimod—skin cancer	0.000532	0.00408	CcSEcCtD
Bismuth Subsalicylate—Hepatitis—Temozolomide—skin cancer	0.000524	0.00402	CcSEcCtD
Bismuth Subsalicylate—PTGS2—female reproductive system—skin cancer	0.000523	0.0114	CbGeAlD
Bismuth Subsalicylate—Hallucination—Temozolomide—skin cancer	0.000522	0.004	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Vemurafenib—skin cancer	0.000516	0.00395	CcSEcCtD
Bismuth Subsalicylate—Lethargy—Docetaxel—skin cancer	0.000514	0.00394	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Imiquimod—skin cancer	0.000512	0.00393	CcSEcCtD
Bismuth Subsalicylate—Epistaxis—Fluorouracil—skin cancer	0.000508	0.00389	CcSEcCtD
Bismuth Subsalicylate—Hyponatraemia—Docetaxel—skin cancer	0.000506	0.00388	CcSEcCtD
Bismuth Subsalicylate—Erythema—Dactinomycin—skin cancer	0.000505	0.00387	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Vemurafenib—skin cancer	0.000499	0.00382	CcSEcCtD
Bismuth Subsalicylate—Erythema multiforme—Temozolomide—skin cancer	0.000496	0.0038	CcSEcCtD
Bismuth Subsalicylate—Urticaria—Imiquimod—skin cancer	0.000494	0.00379	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Imiquimod—skin cancer	0.000491	0.00377	CcSEcCtD
Bismuth Subsalicylate—Tinnitus—Temozolomide—skin cancer	0.000489	0.00375	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Vemurafenib—skin cancer	0.000482	0.0037	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Vemurafenib—skin cancer	0.000463	0.00355	CcSEcCtD
Bismuth Subsalicylate—Abdominal pain upper—Docetaxel—skin cancer	0.00046	0.00353	CcSEcCtD
Bismuth Subsalicylate—Rash—Vemurafenib—skin cancer	0.00046	0.00352	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Vemurafenib—skin cancer	0.000459	0.00352	CcSEcCtD
Bismuth Subsalicylate—PTGS1—head—skin cancer	0.000457	0.00993	CbGeAlD
Bismuth Subsalicylate—Headache—Vemurafenib—skin cancer	0.000457	0.0035	CcSEcCtD
Bismuth Subsalicylate—Erythema—Temozolomide—skin cancer	0.000456	0.0035	CcSEcCtD
Bismuth Subsalicylate—Dysgeusia—Temozolomide—skin cancer	0.000447	0.00343	CcSEcCtD
Bismuth Subsalicylate—Confusional state—Bleomycin—skin cancer	0.000445	0.00341	CcSEcCtD
Bismuth Subsalicylate—Oedema—Bleomycin—skin cancer	0.000442	0.00339	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Imiquimod—skin cancer	0.00044	0.00337	CcSEcCtD
Bismuth Subsalicylate—Infection—Bleomycin—skin cancer	0.000439	0.00336	CcSEcCtD
Bismuth Subsalicylate—PTGS2—head—skin cancer	0.000437	0.00949	CbGeAlD
Bismuth Subsalicylate—Nausea—Vemurafenib—skin cancer	0.000433	0.00332	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Imiquimod—skin cancer	0.000425	0.00326	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Bleomycin—skin cancer	0.000421	0.00323	CcSEcCtD
Bismuth Subsalicylate—Erythema—Fluorouracil—skin cancer	0.000421	0.00322	CcSEcCtD
Bismuth Subsalicylate—Oedema—Dactinomycin—skin cancer	0.000412	0.00316	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Imiquimod—skin cancer	0.000411	0.00315	CcSEcCtD
Bismuth Subsalicylate—Infection—Dactinomycin—skin cancer	0.000409	0.00314	CcSEcCtD
Bismuth Subsalicylate—Weight increased—Docetaxel—skin cancer	0.000396	0.00304	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Imiquimod—skin cancer	0.000395	0.00303	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Dactinomycin—skin cancer	0.000393	0.00301	CcSEcCtD
Bismuth Subsalicylate—Rash—Imiquimod—skin cancer	0.000392	0.003	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Imiquimod—skin cancer	0.000392	0.003	CcSEcCtD
Bismuth Subsalicylate—Headache—Imiquimod—skin cancer	0.000389	0.00299	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Bleomycin—skin cancer	0.000384	0.00294	CcSEcCtD
Bismuth Subsalicylate—Pain—Bleomycin—skin cancer	0.000378	0.00289	CcSEcCtD
Bismuth Subsalicylate—Confusional state—Temozolomide—skin cancer	0.000376	0.00288	CcSEcCtD
Bismuth Subsalicylate—Oedema—Temozolomide—skin cancer	0.000373	0.00286	CcSEcCtD
Bismuth Subsalicylate—Infection—Temozolomide—skin cancer	0.00037	0.00284	CcSEcCtD
Bismuth Subsalicylate—Nausea—Imiquimod—skin cancer	0.000369	0.00283	CcSEcCtD
Bismuth Subsalicylate—Epistaxis—Docetaxel—skin cancer	0.000366	0.00281	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Bleomycin—skin cancer	0.000364	0.00279	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Dactinomycin—skin cancer	0.000358	0.00274	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Temozolomide—skin cancer	0.000355	0.00272	CcSEcCtD
Bismuth Subsalicylate—Pain—Dactinomycin—skin cancer	0.000352	0.0027	CcSEcCtD
Bismuth Subsalicylate—Urticaria—Bleomycin—skin cancer	0.000351	0.00269	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Bleomycin—skin cancer	0.000349	0.00268	CcSEcCtD
Bismuth Subsalicylate—Hepatitis—Docetaxel—skin cancer	0.000349	0.00267	CcSEcCtD
Bismuth Subsalicylate—Confusional state—Fluorouracil—skin cancer	0.000346	0.00265	CcSEcCtD
Bismuth Subsalicylate—Oedema—Fluorouracil—skin cancer	0.000343	0.00263	CcSEcCtD
Bismuth Subsalicylate—Infection—Fluorouracil—skin cancer	0.000341	0.00261	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Dactinomycin—skin cancer	0.000339	0.0026	CcSEcCtD
Bismuth Subsalicylate—Somnolence—Temozolomide—skin cancer	0.000331	0.00254	CcSEcCtD
Bismuth Subsalicylate—Erythema multiforme—Docetaxel—skin cancer	0.00033	0.00253	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Temozolomide—skin cancer	0.000328	0.00251	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Fluorouracil—skin cancer	0.000327	0.00251	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Dactinomycin—skin cancer	0.000326	0.0025	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Temozolomide—skin cancer	0.000324	0.00248	CcSEcCtD
Bismuth Subsalicylate—PTGS1—lymph node—skin cancer	0.00032	0.00695	CbGeAlD
Bismuth Subsalicylate—Constipation—Temozolomide—skin cancer	0.000319	0.00244	CcSEcCtD
Bismuth Subsalicylate—Pain—Temozolomide—skin cancer	0.000319	0.00244	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Bleomycin—skin cancer	0.000312	0.0024	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Temozolomide—skin cancer	0.000307	0.00235	CcSEcCtD
Bismuth Subsalicylate—PTGS2—lymph node—skin cancer	0.000306	0.00664	CbGeAlD
Bismuth Subsalicylate—Somnolence—Fluorouracil—skin cancer	0.000305	0.00234	CcSEcCtD
Bismuth Subsalicylate—Erythema—Docetaxel—skin cancer	0.000304	0.00233	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Fluorouracil—skin cancer	0.000302	0.00232	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Fluorouracil—skin cancer	0.000298	0.00229	CcSEcCtD
Bismuth Subsalicylate—Dysgeusia—Docetaxel—skin cancer	0.000297	0.00228	CcSEcCtD
Bismuth Subsalicylate—Urticaria—Temozolomide—skin cancer	0.000296	0.00227	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Temozolomide—skin cancer	0.000295	0.00226	CcSEcCtD
Bismuth Subsalicylate—Pain—Fluorouracil—skin cancer	0.000294	0.00225	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Fluorouracil—skin cancer	0.000283	0.00217	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Dactinomycin—skin cancer	0.000282	0.00216	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Bleomycin—skin cancer	0.000281	0.00215	CcSEcCtD
Bismuth Subsalicylate—Rash—Bleomycin—skin cancer	0.000278	0.00213	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Bleomycin—skin cancer	0.000278	0.00213	CcSEcCtD
Bismuth Subsalicylate—Urticaria—Fluorouracil—skin cancer	0.000273	0.00209	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Fluorouracil—skin cancer	0.000271	0.00208	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Temozolomide—skin cancer	0.000264	0.00202	CcSEcCtD
Bismuth Subsalicylate—Nausea—Bleomycin—skin cancer	0.000262	0.00201	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Dactinomycin—skin cancer	0.000262	0.00201	CcSEcCtD
Bismuth Subsalicylate—Rash—Dactinomycin—skin cancer	0.00026	0.00199	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Temozolomide—skin cancer	0.000255	0.00195	CcSEcCtD
Bismuth Subsalicylate—Confusional state—Docetaxel—skin cancer	0.00025	0.00191	CcSEcCtD
Bismuth Subsalicylate—Oedema—Docetaxel—skin cancer	0.000248	0.0019	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Temozolomide—skin cancer	0.000246	0.00189	CcSEcCtD
Bismuth Subsalicylate—Infection—Docetaxel—skin cancer	0.000246	0.00189	CcSEcCtD
Bismuth Subsalicylate—Nausea—Dactinomycin—skin cancer	0.000245	0.00188	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Fluorouracil—skin cancer	0.000243	0.00186	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Temozolomide—skin cancer	0.000237	0.00182	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Docetaxel—skin cancer	0.000236	0.00181	CcSEcCtD
Bismuth Subsalicylate—Rash—Temozolomide—skin cancer	0.000235	0.0018	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Fluorouracil—skin cancer	0.000235	0.0018	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Temozolomide—skin cancer	0.000235	0.0018	CcSEcCtD
Bismuth Subsalicylate—Headache—Temozolomide—skin cancer	0.000233	0.00179	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Fluorouracil—skin cancer	0.000227	0.00174	CcSEcCtD
Bismuth Subsalicylate—Nausea—Temozolomide—skin cancer	0.000221	0.0017	CcSEcCtD
Bismuth Subsalicylate—Somnolence—Docetaxel—skin cancer	0.00022	0.00169	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Fluorouracil—skin cancer	0.000218	0.00167	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Docetaxel—skin cancer	0.000218	0.00167	CcSEcCtD
Bismuth Subsalicylate—Rash—Fluorouracil—skin cancer	0.000216	0.00166	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Fluorouracil—skin cancer	0.000216	0.00166	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Docetaxel—skin cancer	0.000215	0.00165	CcSEcCtD
Bismuth Subsalicylate—Headache—Fluorouracil—skin cancer	0.000215	0.00165	CcSEcCtD
Bismuth Subsalicylate—Constipation—Docetaxel—skin cancer	0.000212	0.00162	CcSEcCtD
Bismuth Subsalicylate—Pain—Docetaxel—skin cancer	0.000212	0.00162	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Docetaxel—skin cancer	0.000204	0.00156	CcSEcCtD
Bismuth Subsalicylate—Nausea—Fluorouracil—skin cancer	0.000204	0.00156	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Docetaxel—skin cancer	0.000196	0.0015	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Docetaxel—skin cancer	0.000175	0.00134	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Docetaxel—skin cancer	0.00017	0.0013	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Docetaxel—skin cancer	0.000164	0.00126	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Docetaxel—skin cancer	0.000158	0.00121	CcSEcCtD
Bismuth Subsalicylate—Rash—Docetaxel—skin cancer	0.000156	0.0012	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Docetaxel—skin cancer	0.000156	0.0012	CcSEcCtD
Bismuth Subsalicylate—Headache—Docetaxel—skin cancer	0.000155	0.00119	CcSEcCtD
Bismuth Subsalicylate—Nausea—Docetaxel—skin cancer	0.000147	0.00113	CcSEcCtD
